Title: Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
Abstract: We previously reported results of a randomised, open-label, phase 2 trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma who had progressed after one previous VEGF-targeted therapy. 1 Motzer RJ Hutson TE Glen H et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015; 16: 1473-1482 Summary Full Text Full Text PDF PubMed Scopus (662) Google Scholar Our study met the primary endpoint by showing improved progression-free survival with lenvatinib plus everolimus and lenvatinib alone versus everolimus alone, using investigator-assessed objective responses. On the basis of agreements reached with regulatory agencies, an ad hoc, retrospective, blinded, independent radiological review (IRR) was completed to assess whether the efficacy results based on investigator assessments were supported by those of the IRR. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialLenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. Further study of lenvatinib is warranted in patients with metastatic renal cell carcinoma. Full-Text PDF